Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

This study is testing a personalized cancer vaccine combined with an immunotherapy drug (a checkpoint inhibitor) for women with triple-negative breast cancer — a type of breast cancer that does not have hormone receptors or HER2 protein and is harder to treat. The personalized vaccine is made from the patient's own tumor mutations to train the immune system to attack the cancer. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with triple-negative breast cancer - Your physical performance (ECOG score) is 0 or 1 - Your blood counts and organ function are within acceptable ranges (checked within 14 days before vaccination) **You may NOT be eligible if:** - Your blood counts are too low (low white cells, platelets, or hemoglobin) - Your kidney or liver function is too poor - You have an active autoimmune condition requiring systemic treatment - You have received prior immunotherapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.